Nektar Therapeutics header image

Nektar Therapeutics

NKTR

Equity

ISIN null / Valor 1542642

NASDAQ (2026-08-07)
USD 76.48+4.13%

Nektar Therapeutics
UMushroom community rating:

star star star star star
4.83 2 votes No rating yet
NegativeNeutralPositive

About company

Nektar Therapeutics is a global biopharmaceutical entity engaged in the discovery, development, and commercialization of innovative therapies. The company specializes in leveraging its profound expertise in immunology and polymer chemistry to develop treatments that precisely modulate the immune system. Its primary focus is on addressing autoimmune disorders, aiming to produce unique, highly-selective medicines designed to offer superior therapeutic benefits. Through its commitment to scientific innovation, Nektar Therapeutics seeks to fulfill unmet medical needs by creating a pipeline of products that stand out for their specificity and efficacy in treating complex diseases.

Summarized from source with an LLMView SourceSector:

Latest Results ():

Summarized from source with an LLMView Source

Key figures

252%1Y
400%3Y
-67.7%5Y

Performance

84.3%1Y
111%3Y
110%5Y

Volatility

Market cap

2584 M

Market cap (USD)

Daily traded volume (Shares)

899,158

Daily traded volume (Shares)

1 day high/low

0.9513 / 0.9301

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.83

2 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
4.00
Aiman Harith Muhaimin Agos Sawal
UK, 18 May 2026
star star star star star
Big upside potential
Arben Hasanaj
Switzerland, 27 Mar 2025
star star star star star
Grosses Potenzial von den klinischen Kandidaten